Cpit (Check Point Inhibitor Trial) 002: Phase I Study of Single-Agent and Combined Checkpoint Inhibition (CI) after Allogenic Hematopoietic Stem Cell Transplantation (alloHCT) in Patients at High Risk for Post-Transplant Recurrence

Jamie Koprivnikar(Hackensack University Medical Center), Andrew L. Pecora(Hackensack University Medical Center), Robert Korngold(Georgetown University), Scott D. Rowley(Johns Hopkins Hospital), Rena Feinman(Georgetown University), Themba Nyirenda(Hackensack University Medical Center), Michèle L. Donato(The University of Texas Health Science Center at Houston), James McCloskey(Hackensack University Medical Center)

Blood

November 13, 2019

10.1182/blood-2019-132025

Cited by 0

Related Papers

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

|Journal of Clinical Oncology|1998|927

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

|The Lancet|2024|729

High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: comparison of autologous bone marrow and peripheral blood stem cells.

|PubMed|1996|645

Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

|Blood|2001|516

Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide

|New England Journal of Medicine|1986|441